As I assume the leadership of the Gates Institute, I have the privilege of having watched the field of cell and gene therapy evolve and the optimism that the Anschutz Medical Campus is positioned to be a major contributor to the next chapter.
Recent therapeutic advances have been developed based upon innovative science with early human proof of concept at academic institutions, followed by commercialization in industry. I believe that the transformative early development will continue to occur at a few leading academic institutions. I also feel strongly that the University of Colorado Anschutz Medical Campus is poised to be one of those institutions and that our region is positioned to be the next major biotech hub.
I am thrilled about my new role and the opportunity to work with the many talented individuals on the campus and in the region to help realize the potential made possible by Charlie Gates’ vision and the generosity of Diane Gates Wallach and her late brother John Gates.
Terry Fry, MD
Executive Director, Gates Institute
University of Colorado Anschutz Medical Campus
The state-of-the-art Gates Biomanufacturing Facility is an FDA-compliant Good Manufacturing Practices facility with 21,000 square feet of space at Fitzsimons Innovation Campus.
Gates Institute is committed to training the next generation of cell and gene therapy researchers through the Gates Summer Internship Program, the Gates Institute Seminar Series and the Graduate Program in Cell Biology, Stem Cells and Development.
Gates Institute offers funding opportunities through the Gates Grubstake Fund. To date, nearly $10 million has been awarded across 29 projects.